Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

hexal ag, holzkirchen array - 13226 hemihydrÁt estradiolu - transdermální náplast - 25mcg/24h - estradiol

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

hexal ag, holzkirchen array - 13226 hemihydrÁt estradiolu - transdermální náplast - 50mcg/24h - estradiol

Evropská unie - čeština - EMA (European Medicines Agency)

amgen europe b.v. - adalimumab - arthritis, psoriatic; spondylitis, ankylosing; crohn disease; colitis, ulcerative; hidradenitis suppurativa; psoriasis; arthritis, rheumatoid - imunosupresiva - viz část 4. 1 souhrnu údajů o přípravku v dokumentu o informacích o přípravku.

Evropská unie - čeština - EMA (European Medicines Agency)

biosimilar collaborations ireland limited - adalimumab - hidradenitis suppurativa; psoriasis; uveitis; arthritis, rheumatoid; spondylitis, ankylosing; crohn disease; colitis, ulcerative; arthritis, psoriatic - imunosupresiva, tumor nekrotizující faktor alfa (tnf-α inhibitory)

Evropská unie - čeština - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - adalimumab - arthritis, rheumatoid; arthritis, psoriatic; psoriasis; spondylitis, ankylosing; uveitis; hidradenitis suppurativa; colitis, ulcerative; crohn disease; arthritis, juvenile rheumatoid - imunosupresiva - rheumatoid arthritisyuflyma in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. adalimumabu bylo prokázáno, že snižuje rychlost progrese kloubního poškození měřeného pomocí rtg a že zlepšuje fyzické funkce, pokud je podáván v kombinaci s methotrexátem. juvenile idiopathic arthritispolyarticular juvenile idiopathic arthritisyuflyma in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5. adalimumab nebyl zkoumán u pacientů ve věku méně než 2 roky. enthesitis-related arthritisyuflyma is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5. axial spondyloarthritisankylosing spondylitis (as)yuflyma is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of asyuflyma is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and/or mri, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). psoriatic arthritisyuflyma is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. adalimumabu bylo prokázáno snížení rychlosti progrese poškození periferních kloubů, měřeno pomocí rtg u pacientů se symetrickým polyartikulárním subtypem onemocnění (viz bod 5. 1) a zlepšení fyzických funkcí. psoriasisyuflyma is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasisyuflyma is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs)yuflyma is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 a 5. crohn’s diseaseyuflyma is indicated for treatment of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's diseaseyuflyma is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies. ulcerative colitisyuflyma is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. paediatric ulcerative colitisyuflyma is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitisyuflyma is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid- sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitisyuflyma is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Evropská unie - čeština - EMA (European Medicines Agency)

csl behring gmbh - lidský koagulační faktor viii a lidský von willebrandův faktor - hemophilia a; von willebrand diseases - blood coagulation factors, von willebrand factor and coagulation factor viii in combination, antihemorrhagics - von willebrandova choroba (vwd)profylaxe a léčba krvácení či chirurgické krvácení u pacientů s vwd, když desmopressin (ddavp) léčba je neúčinná nebo kontraindikována. hemofilie a (vrozený faktor-viii nedostatek)profylaxe a léčba krvácení u pacientů s hemofilií a.

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

baxalta innovations gmbh, vídeň array - 3531 lidskÝ koagulaČnÍ faktor viii; 17457 lidskÝ von willebrandŮv faktor - prášek a rozpouštědlo pro injekční roztok - 1000iu/750iu - koagulaČnÍ faktor viii a von willebrandŮv faktor v kombinaci

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

baxalta innovations gmbh, vídeň array - 3531 lidskÝ koagulaČnÍ faktor viii; 17457 lidskÝ von willebrandŮv faktor - prášek a rozpouštědlo pro injekční roztok - 500iu/375iu - koagulaČnÍ faktor viii a von willebrandŮv faktor v kombinaci

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

biotest pharma gmbh, dreieich array - 3531 lidskÝ koagulaČnÍ faktor viii - prášek a rozpouštědlo pro injekční roztok - 1000iu - koagulaČnÍ faktor viii

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

biotest pharma gmbh, dreieich array - 3531 lidskÝ koagulaČnÍ faktor viii - prášek a rozpouštědlo pro injekční roztok - 250iu - koagulaČnÍ faktor viii